Fagron N.V. : Q3 2023: North America to be the growth driver
>We expect growth to be concentrated in North America in H2 2023 - Fagron is set to report Q3 2023 trading update on 12 October. Overall, we expect Q3 2023 to have performed better than Q3 2022. Regarding EMEA, the pricing pass-through was very important and drove a major segment of revenue. It was completed in H1 2023. In LATAM, Fagron highlights high competition (despite demand improving). In North America, overall, we expect growth to have been supported by Anazao’...Fagron supplies products, services to professionals and institutions in the healthcare sector in Europe, the U.S.A. and Brazil. Co.'s activities are subdivided into four divisions. Through Fagron, Co. offers products and concepts for pharmaceutical compounding. Through Arseus Dental, Co. supplies dental products and concepts to dentists and dental laboratories in Belgium, the Netherlands, France, Germany and Switzerland. Through Arseus Medical, Co. supplies medical and surgical products to specialists, elderly homes, homecare nurses and hospitals in Belgium and the Netherlands. Through Corilus, Co. supplies ICT total solutions for medical specialists in Belgium, the Netherlands and France.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.